InstituteHBDH
Welcome,         Profile    Billing    Logout  
 10 Trials 
51 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiaofan, Zhu
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Ye, Guo
NCT05027204: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)

Recruiting
1/2
94
RoW
Docetaxel, Nivolumab
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
10/23
12/23
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Wenyu, Yang
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Xiaojuan, Chen
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Min, Ruan
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Yumei, Chen
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Qi, JunYuan
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Checkmark Efficacy data from trial in combination with azacitidine for MDS
Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
Checkmark Data from a study in combination with azacitidine for MDS at ESMO 2022
Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022
Completed
1/2
105
RoW
TJ011133
TJ Biopharma Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
12/23
12/23
NCT06021678: Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Recruiting
1/2
415
RoW
EX103 injection, EX103, bispecific monoclonal antibody that recognizes both CD3 and CD20
Guangzhou Excelmab Inc.
CD20-positive Non-Hodgkin Lymphoma
10/25
12/25
NCT05011097: A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Recruiting
1
75
RoW
Y150
Wuhan YZY Biopharma Co., Ltd.
Relapsed or Refractory Multiple Myeloma
07/23
12/24
NTP-F182112-001, NCT04984434: Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
1
68
RoW
F182112
Shandong New Time Pharmaceutical Co., LTD
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
07/23
12/23
HY-XY0206-Ⅰ-02, NCT04471064: A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

Recruiting
1
60
RoW
XY0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd, Proswell Medical Corporation
Acute Myeloid Leukemia
02/24
02/24
NCT05758610: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Recruiting
1
60
RoW
ETH-155008, Study drug
Shengke Pharmaceuticals (Jiangsu) Limited, China
NHL, Adult, AML, Adult Recurrent
12/25
06/26
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Recruiting
1
41
RoW
GNC-038
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
06/25
11/25
NCT06888960: Safety Study of CC312 in Autoimmune Disease Patients

Recruiting
1
18
RoW
CC312
CytoCares Inc
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Primary Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia
11/26
11/26
NCT06037018: Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Recruiting
1
44
RoW
CC312
CytoCares Inc
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
03/25
03/26
NCT06894693: A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

Not yet recruiting
1
13
NA
RS001 injection
Guangdong Ruishun Biotech Co., Ltd
B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia
04/26
04/28
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
26
RoW
BL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
08/25
08/25
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting
1
102
RoW
APG-115, Azacitidine, Cytarabine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
12/25
12/25
HC1702-BE-001, NCT04920500: Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients

Recruiting
N/A
16
RoW
Daunorubicin Cytarabine liposome for injection, Vyxeos、Daunorubicin Cytarabine liposome for injection, Vyxeos
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Acute Myeloid Leukemia
06/21
06/21
NCT05801835: A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Recruiting
N/A
36
RoW
(cytarabine: daunorubicin) liposome for injection, Vyxeos, CPX-351
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Acute Myeloid Leukemia
04/25
12/25
An, Gang
FUMANBA-03, NCT06464991: A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM

Recruiting
3
240
RoW
Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
08/27
12/30
NCT06793449: BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Recruiting
2
80
RoW
anti-BCMA CAR-T, ASCT
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
12/26
12/30
NCT06880393: BCMA CAR-T for Dynamic High-risk Multiple Myeloma

Recruiting
2
40
RoW
anti-BCMA-CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
12/26
01/28
CAREMM-001, NCT05860036: A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Recruiting
2
40
RoW
anti-BCMA CAR-T, VRd
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
03/25
03/28
CAC-MM-001, NCT05850286: A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Recruiting
2
20
RoW
anti-BCMA CAR-T, VRD-based Regimen
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
04/25
04/27
NCT05870917: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Recruiting
2
20
RoW
anti-BCMA CAR-T, Bortezomib, Lenalidomide and Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Plasma Cell Leukemia
04/25
04/27
NCT06952075: GR1803 Injection in Patients With RRMM

Recruiting
2
30
RoW
GR1803
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Multiple Myleoma
07/27
12/27
NCT05846737: BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Recruiting
2
20
RoW
anti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
05/25
05/28
NCT07039578: Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Recruiting
2
90
RoW
CM336 Injection(Low dose group), CM336 Injection(High dose group)
Keymed Biosciences Co.Ltd
Primary Light-Chain Amyloidosis
06/26
07/29
NCT05979363: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Recruiting
2
20
RoW
anti-BCMA CAR-T, VRD-based regimen
Institute of Hematology & Blood Diseases Hospital
Plasma Cell Leukemia
07/25
07/28
NCT07018050: Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Not yet recruiting
2
160
RoW
QLS32015, Pomalidomide, Dexamethasone, QL2109 or Daratumumab, Bortezomib, Lenalidomide
Qilu Pharmaceutical Co., Ltd.
Relapsed or Refractory Multiple Myeloma
11/27
07/28
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT05549973: Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Recruiting
1
32
RoW
Anlotinib Hydrochloride Capsule, dexamethasone
Institute of Hematology & Blood Diseases Hospital
Multiple Myeloma
07/23
07/24
NCT05376345: BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
1
32
RoW
LCAR-BCDR cells product
Weijun Fu, Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
06/24
09/26
NCT06500507: A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Not yet recruiting
1
90
RoW
QLS4131 Injection, A novel tri-specific humanized antibody
Qilu Pharmaceutical Co., Ltd.
Relapsed or Refractory Multiple Myeloma
03/26
01/27
NCT05913804: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1
8
RoW
YTS104 Cells injection
Institute of Hematology & Blood Diseases Hospital, China Immunotech (Beijing) Biotechnology Co., Ltd.
Relapsed or Refractory Multiple Myeloma
12/25
12/25
NCT06745687: BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Not yet recruiting
N/A
20
RoW
CM336
Institute of Hematology & Blood Diseases Hospital, China, Keymed Biosciences Co.Ltd
High Risk Smoldering Multiple Myeloma
08/26
08/28
NCT06793475: Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Recruiting
N/A
20
RoW
anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib, Thalidomide, Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Extramedullary Multiple Myeloma
06/26
12/26
NCT05536700: Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Recruiting
N/A
67
RoW
Institute of Hematology & Blood Diseases Hospital, Shanghai Kuaixu Biotechnology Co., Ltd
Multiple Myeloma
09/22
12/22
NCT05578625: ctDNA Methylation Sequencing for Myeloma

Recruiting
N/A
66
RoW
plasma circulation DNA methylation sequencing
Institute of Hematology & Blood Diseases Hospital, MethylGene Tech Co., Ltd. China
Multiple Myeloma
08/23
06/25
Zhang, Jingliao
CCCG-I/HR-ALL, NCT06764238: Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Recruiting
2/3
1800
RoW
Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B)
Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
12/29
06/31
NCT05495035: Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Recruiting
1
22
RoW
Olverembatinib, APG-2575, Dexamethasone
Institute of Hematology & Blood Diseases Hospital
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
08/24
12/24
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
JING, ZHEN
NCT06037018: Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Recruiting
1
44
RoW
CC312
CytoCares Inc
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
03/25
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiaofan, Zhu
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Ye, Guo
NCT05027204: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)

Recruiting
1/2
94
RoW
Docetaxel, Nivolumab
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
10/23
12/23
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Wenyu, Yang
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Xiaojuan, Chen
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Min, Ruan
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Yumei, Chen
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
AML-CAMS-2016, NCT03173612: The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Recruiting
N/A
132
RoW
Dasatinib, cytarabine(Ara-C), etoposide(VP-16), idarubicin(IDA), aclacinomycin(Acla), granulocyte colony-stimulating factor(G-CSF), Mitoxantrone
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
12/24
12/24
Qi, JunYuan
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Checkmark Efficacy data from trial in combination with azacitidine for MDS
Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
Checkmark Data from a study in combination with azacitidine for MDS at ESMO 2022
Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022
Completed
1/2
105
RoW
TJ011133
TJ Biopharma Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
12/23
12/23
NCT06021678: Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Recruiting
1/2
415
RoW
EX103 injection, EX103, bispecific monoclonal antibody that recognizes both CD3 and CD20
Guangzhou Excelmab Inc.
CD20-positive Non-Hodgkin Lymphoma
10/25
12/25
NCT05011097: A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Recruiting
1
75
RoW
Y150
Wuhan YZY Biopharma Co., Ltd.
Relapsed or Refractory Multiple Myeloma
07/23
12/24
NTP-F182112-001, NCT04984434: Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
1
68
RoW
F182112
Shandong New Time Pharmaceutical Co., LTD
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
07/23
12/23
HY-XY0206-Ⅰ-02, NCT04471064: A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

Recruiting
1
60
RoW
XY0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd, Proswell Medical Corporation
Acute Myeloid Leukemia
02/24
02/24
NCT05758610: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Recruiting
1
60
RoW
ETH-155008, Study drug
Shengke Pharmaceuticals (Jiangsu) Limited, China
NHL, Adult, AML, Adult Recurrent
12/25
06/26
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Recruiting
1
41
RoW
GNC-038
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
06/25
11/25
NCT06888960: Safety Study of CC312 in Autoimmune Disease Patients

Recruiting
1
18
RoW
CC312
CytoCares Inc
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Primary Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia
11/26
11/26
NCT06037018: Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Recruiting
1
44
RoW
CC312
CytoCares Inc
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
03/25
03/26
NCT06894693: A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

Not yet recruiting
1
13
NA
RS001 injection
Guangdong Ruishun Biotech Co., Ltd
B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia
04/26
04/28
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
26
RoW
BL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
08/25
08/25
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting
1
102
RoW
APG-115, Azacitidine, Cytarabine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
12/25
12/25
HC1702-BE-001, NCT04920500: Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients

Recruiting
N/A
16
RoW
Daunorubicin Cytarabine liposome for injection, Vyxeos、Daunorubicin Cytarabine liposome for injection, Vyxeos
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Acute Myeloid Leukemia
06/21
06/21
NCT05801835: A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Recruiting
N/A
36
RoW
(cytarabine: daunorubicin) liposome for injection, Vyxeos, CPX-351
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Acute Myeloid Leukemia
04/25
12/25
An, Gang
FUMANBA-03, NCT06464991: A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM

Recruiting
3
240
RoW
Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone
Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
08/27
12/30
NCT06793449: BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Recruiting
2
80
RoW
anti-BCMA CAR-T, ASCT
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
12/26
12/30
NCT06880393: BCMA CAR-T for Dynamic High-risk Multiple Myeloma

Recruiting
2
40
RoW
anti-BCMA-CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
12/26
01/28
CAREMM-001, NCT05860036: A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Recruiting
2
40
RoW
anti-BCMA CAR-T, VRd
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
03/25
03/28
CAC-MM-001, NCT05850286: A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Recruiting
2
20
RoW
anti-BCMA CAR-T, VRD-based Regimen
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
04/25
04/27
NCT05870917: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Recruiting
2
20
RoW
anti-BCMA CAR-T, Bortezomib, Lenalidomide and Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Plasma Cell Leukemia
04/25
04/27
NCT06952075: GR1803 Injection in Patients With RRMM

Recruiting
2
30
RoW
GR1803
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Multiple Myleoma
07/27
12/27
NCT05846737: BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Recruiting
2
20
RoW
anti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
05/25
05/28
NCT07039578: Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Recruiting
2
90
RoW
CM336 Injection(Low dose group), CM336 Injection(High dose group)
Keymed Biosciences Co.Ltd
Primary Light-Chain Amyloidosis
06/26
07/29
NCT05979363: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Recruiting
2
20
RoW
anti-BCMA CAR-T, VRD-based regimen
Institute of Hematology & Blood Diseases Hospital
Plasma Cell Leukemia
07/25
07/28
NCT07018050: Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Not yet recruiting
2
160
RoW
QLS32015, Pomalidomide, Dexamethasone, QL2109 or Daratumumab, Bortezomib, Lenalidomide
Qilu Pharmaceutical Co., Ltd.
Relapsed or Refractory Multiple Myeloma
11/27
07/28
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT05549973: Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Recruiting
1
32
RoW
Anlotinib Hydrochloride Capsule, dexamethasone
Institute of Hematology & Blood Diseases Hospital
Multiple Myeloma
07/23
07/24
NCT05376345: BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
1
32
RoW
LCAR-BCDR cells product
Weijun Fu, Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
06/24
09/26
NCT06500507: A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Not yet recruiting
1
90
RoW
QLS4131 Injection, A novel tri-specific humanized antibody
Qilu Pharmaceutical Co., Ltd.
Relapsed or Refractory Multiple Myeloma
03/26
01/27
NCT05913804: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1
8
RoW
YTS104 Cells injection
Institute of Hematology & Blood Diseases Hospital, China Immunotech (Beijing) Biotechnology Co., Ltd.
Relapsed or Refractory Multiple Myeloma
12/25
12/25
NCT06745687: BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Not yet recruiting
N/A
20
RoW
CM336
Institute of Hematology & Blood Diseases Hospital, China, Keymed Biosciences Co.Ltd
High Risk Smoldering Multiple Myeloma
08/26
08/28
NCT06793475: Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Recruiting
N/A
20
RoW
anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib, Thalidomide, Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Extramedullary Multiple Myeloma
06/26
12/26
NCT05536700: Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Recruiting
N/A
67
RoW
Institute of Hematology & Blood Diseases Hospital, Shanghai Kuaixu Biotechnology Co., Ltd
Multiple Myeloma
09/22
12/22
NCT05578625: ctDNA Methylation Sequencing for Myeloma

Recruiting
N/A
66
RoW
plasma circulation DNA methylation sequencing
Institute of Hematology & Blood Diseases Hospital, MethylGene Tech Co., Ltd. China
Multiple Myeloma
08/23
06/25
Zhang, Jingliao
CCCG-I/HR-ALL, NCT06764238: Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Recruiting
2/3
1800
RoW
Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B)
Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
12/29
06/31
NCT05495035: Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Recruiting
1
22
RoW
Olverembatinib, APG-2575, Dexamethasone
Institute of Hematology & Blood Diseases Hospital
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
08/24
12/24
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
N/A
60
RoW
CAR T cell injection
Zhu Xiaofan
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
12/26
01/27
JING, ZHEN
NCT06037018: Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Recruiting
1
44
RoW
CC312
CytoCares Inc
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
03/25
03/26

Download Options